Omeros Corporation (NASDAQ:OMER) and Oragenics Inc. (NYSEAMERICAN:OGEN) compete against each other in the Biotechnology sector. We will contrast them and contrast their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
Table 1 shows gross revenue, earnings per share and valuation of the two companies.
Table 2 provides us Omeros Corporation and Oragenics Inc.’s return on assets, return on equity and net margins.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Omeros Corporation’s current beta is 3.57 and it happens to be 257.00% more volatile than S&P 500. In other hand, Oragenics Inc. has beta of 1.71 which is 71.00% more volatile than S&P 500.
2.7 and 2.7 are the respective Current Ratio and a Quick Ratio of Omeros Corporation. Its rival Oragenics Inc.’s Current and Quick Ratios are 9.9 and 9.9 respectively. Oragenics Inc. has a better chance of clearing its pay short and long-term debts than Omeros Corporation.
The table shown features the ratings and recommendations for Omeros Corporation and Oragenics Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
Omeros Corporation’s upside potential is 57.13% at a $28 consensus target price.
Institutional & Insider Ownership
Roughly 49.8% of Omeros Corporation shares are held by institutional investors while 12.4% of Oragenics Inc. are owned by institutional investors. Insiders held 0.4% of Omeros Corporation shares. Competitively, insiders own roughly 6.89% of Oragenics Inc.’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
For the past year Omeros Corporation has stronger performance than Oragenics Inc.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use during cataract surgery or intraocular lens replacement. Its clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases. The companyÂ’s clinical programs also consists of OMS824, which is in Phase II clinical trial for the treatment of Huntington's diseases and schizophrenia; OMS405 that is in Phase II clinical trial to treat opioid and nicotine addiction; and OMS201, which is in Phase I/II clinical trial for use during urological procedures. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; OMS721 for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and OMS616 to control surgical and traumatic bleeding. The companyÂ’s preclinical programs also include GPR17 for the treatment of myelin formation; GPR101 for appetite and eating disorders; GPR151 to treat schizophrenia and cognition; GPR161 for triple-negative breast cancer treatment; GPR183 for the treatment of osteoporosis, and Epstein-Barr virus infections and related diseases; GPR174 for modulation of the immune system; and Antibody Platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. In addition, the company is developing OMS103 that has completed Phase III clinical trial for arthroscopic anterior cruciate ligament reconstruction and arthroscopic partial meniscectomy. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in initiation of Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its products also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has license agreement with Intrexon Corporation to use its technology to develop lantibiotics; and Intrexon Corporation and its wholly owned subsidiary, Actobiotics NV to use their intellectual property to develop AG013. It also has license agreement with LPThera LLC to develop LPT3-04 weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.